NCT02986906

Perineural Injection Therapy for Ulnar Neuropathy at Elbow

Completed NA Last updated 20 November 2019

What this trial tests

NA trial testing 5% dextrose in Ulnar Neuropathy at Elbow in 36 participants. Completed in 30 October 2019.

Timeline

1 March 2017

Primary endpoint
30 October 2019

30 October 2019

Quick facts

Lead sponsor	Tri-Service General Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	36
Start date	1 March 2017
Primary completion	30 October 2019
Estimated completion	30 October 2019
Sites	1 location across Taiwan

Drugs / interventions tested

• 5% dextrose — full drug profile →
• 2cc 0.9% normal saline+3cc Triamcinolone (30mg) — full drug profile →
• Ultrasound

Conditions studied

• Ulnar Neuropathy at Elbow — all drugs for Ulnar Neuropathy at Elbow →

Sponsor

Tri-Service General Hospital

Who can join

Adults 20 to 80, any sex, with Ulnar Neuropathy at Elbow. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ulnar neuropathy at elbow (UNE) is the second common peripheral entrapment neuropathy. Although many conservative managements of UNE, the effectiveness of these methods are unsatisfied especial the moderate degree of UNE. Recently, ultrasound-guided perineural injection therapy (PIT) with 5% dextrose is progressively applicated for clinical treatment for entrapment neuropathy. However, current studies have not proved the effects of PIT on peripheral neuropathy because these studies enrolled small number of patients and lacked controlled design. We design a randomized, double-blind, controlled trail to assess the effect after ultrasound-guided PIT with 5% dextrose in patients with mild and moderate UNE.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.